1.
Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-...
by Cahn, Pedro, Dr
The Lancet infectious diseases, 2014, Vol.14 (7), p.572-580
2.
Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial
by Molina, Jean-Michel, Dr, Prof
The Lancet (British edition), 2011, Vol.378 (9787), p.238-246
3.
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial
by Madruga, José Valdez, Dr
The Lancet (British edition), 2007, Vol.370 (9581), p.29-38
4.
The HIV care continuum in Latin America: challenges and opportunities
by Piñeirúa, Alicia, MD
The Lancet infectious diseases, 2015, Vol.15 (7), p.833-839
5.
Should active recruitment of health workers from sub-Saharan Africa be viewed as a crime?
by Mills, Edward J, Dr
The Lancet (British edition), 2008, Vol.371 (9613), p.685-688
6.
Comparative studies of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudine
by HAAS, David W
AIDS (London), 2000, Vol.14 (13), p.1973-1978
7.
Antiretroviral Resistance among HIV Type 1-Infected Women First Exposed to Antiretrovirals during Pregnancy: Plasma versus PBMCs
by Soto-Ramirez, Luis E.
AIDS research and human retroviruses, 2008, Vol.24 (6), p.797-804
